Global Human Alpha1-Proteinase Inhibitor Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Human Alpha1-Proteinase Inhibitor Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Alpha1-Proteinase Inhibitor (Human), is a sterile, stable, lyophilized preparation of highly purified human alpha1-proteinase inhibitor (A1-PI)
Human Alpha1-Proteinase Inhibitor report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Human Alpha1-Proteinase Inhibitor market is projected to reach US$ 293.1 million in 2029, increasing from US$ 218 million in 2022, with the CAGR of 4.2% during the period of 2024 to 2029. Demand from Hospital and Pharmacy are the major drivers for the industry.
The market growth can be attributed to several factors. Firstly, increasing awareness and improved diagnosis of AATD have led to a better identification of patients with this condition, driving the demand for Alpha1-PI therapy. Additionally, advancements in biotechnology and protein manufacturing techniques have contributed to the development of highly purified and more effective Alpha1-PI products, offering improved treatment options for patients.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Alpha1-Proteinase Inhibitor market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Takeda
Kamada
Grifols
CSL Behring
Segment by Type
0.5g
1g
Hospital
Pharmacy
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Human Alpha1-Proteinase Inhibitor market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Human Alpha1-Proteinase Inhibitor, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Human Alpha1-Proteinase Inhibitor industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Human Alpha1-Proteinase Inhibitor in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Human Alpha1-Proteinase Inhibitor introduction, etc. Human Alpha1-Proteinase Inhibitor Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Human Alpha1-Proteinase Inhibitor market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Human Alpha1-Proteinase Inhibitor report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Human Alpha1-Proteinase Inhibitor market is projected to reach US$ 293.1 million in 2029, increasing from US$ 218 million in 2022, with the CAGR of 4.2% during the period of 2024 to 2029. Demand from Hospital and Pharmacy are the major drivers for the industry.
The market growth can be attributed to several factors. Firstly, increasing awareness and improved diagnosis of AATD have led to a better identification of patients with this condition, driving the demand for Alpha1-PI therapy. Additionally, advancements in biotechnology and protein manufacturing techniques have contributed to the development of highly purified and more effective Alpha1-PI products, offering improved treatment options for patients.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Alpha1-Proteinase Inhibitor market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Takeda
Kamada
Grifols
CSL Behring
Segment by Type
0.5g
1g
Segment by Application
Hospital
Pharmacy
Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Human Alpha1-Proteinase Inhibitor market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Human Alpha1-Proteinase Inhibitor, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Human Alpha1-Proteinase Inhibitor industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Human Alpha1-Proteinase Inhibitor in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Human Alpha1-Proteinase Inhibitor introduction, etc. Human Alpha1-Proteinase Inhibitor Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Human Alpha1-Proteinase Inhibitor market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices